Response to ‘Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child–Pugh B Hepatocellular Carcinoma’

Liver International 2026 Open access

Read full text
Authors: Ryu Sasaki, Shigeo Shimose, Issei Saeki, Hisamitsu Miyaaki, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group
DOI: 10.1111/liv.70547
Cited by: 0
References: 3

Abstract

We sincerely thank Xiang et al. for their insightful comments on our study titled 'Efficacy and safety of atezolizumab plus bevacizumab for patients with hepatocellular carcinoma and Child-Pugh class B' [1,2].We carefully reviewed each point raised and present our responses below.

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Liver International
Volume
46
Issue
3
Pages
e70547–e70547
Publication date
6 February 2026
Language
EN